Teitur Trophics today announce the dosing of the first two patients with Parkinson’s disease in the Phase I trial for TT-P34, conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. This milestone marks a significant step forward in Teitur’s mission to accelerate the development of their lead compound TT-P34.
The clinical trial is no actively enrolling and dosing Parkinson’s patients, focusing on evaluating the safety and tolerability of TT-P34. Teitur’s lead compound is designed to restore lysosomal and mitochondrial function, both fundamental aspects of the underlying disease biology in neurodegenerative diseases. The trial is conducted at CHDR’s clinical research facility, and is designed to evaluate early data on tolerability and pharmacology.
“We are excited to reach this pivotal moment in the Phase I program for TT-P34,” said Andreas Borta, CMO of Teitur Trophics. “Initiating patient dosing at CHDR is a major milestone for Teitur Trophics and is the result of years of scientific innovation of our entire team and multiple cross-disciplinary collaborations. It represents a meaningful advance toward our goal of developing novel therapies that could slow-down or even completely halt the progression of Parkinson’s disease.”
The trial in Leiden, conducted in partnership with CHDR, incorporates numerous clinical assessments alongside the collection of biomarkers from cerebrospinal fluid to explore how TT-P34 impacts lysosomal and mitochondrial pathways and overall improves neuronal functioning.
About Teitur Trophics
Teitur Trophics ApS, based in Aarhus, Denmark, is a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases. Founded as a spin-out from Aarhus University, Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function. The company’s lead drug candidate, TT-P34, targets the three major pathophysiological hallmarks of neurodegeneration with the potential to treat Parkinson’s disease, Huntington’s disease, and Frontotemporal dementia.
For more information,visit teiturtrophics.com.
About CHDR
The Centre for Human Drug Research (CHDR) in Leiden is a leading clinical pharmacology institute with expertise in early phase drug development and biomarker-driven research. CHDR conducts a broad portfolio of clinical trials in neurology, immunology, and other therapeutic areas, supporting global pharmaceutical and biotech partners in translating scientific discoveries into new medicines.
For more information,visit chdr.nl
About TT-P34
TT-P34 is Teitur Trophics’ lead, first-in-class cyclic peptide drug candidate designed as a potential disease-modifying therapy for neurodegenerative disorders, including Parkinson’s disease. TT-P34 is a subcutaneously administered peptide aiming to preserve neuronal function and survival by addressing key cellular pathologies that drive neurodegeneration, including improvement of lysosomal and mitochondrial function in neurons.
